NO20055654L - Azetidinkarboksamidderivater og deres anvendelse ved behandling av CBI-reseptormediserte forstyrrelser - Google Patents
Azetidinkarboksamidderivater og deres anvendelse ved behandling av CBI-reseptormediserte forstyrrelserInfo
- Publication number
- NO20055654L NO20055654L NO20055654A NO20055654A NO20055654L NO 20055654 L NO20055654 L NO 20055654L NO 20055654 A NO20055654 A NO 20055654A NO 20055654 A NO20055654 A NO 20055654A NO 20055654 L NO20055654 L NO 20055654L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- mediated disorders
- carboxamide derivatives
- cbi receptor
- azetidine carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Forbindelser med formel (I) og deres anvendelse i behandling, fortrirmsvis for behandling av en forstyrrelse som formidles av CBi-reseptorer, feks. fedme: hvori: R' og R^ uavhengig av hverandre er utvalgt blant aryl og R^ er hydrogen eller alkyl, eller et farmasøytisk aksepterbart salt eller promedikament derav, hvori minst én av R' og R^ har en ikke- hydrogensubstituenti orto-posisjonen eller -posisjonene relativt til tilkoblings-punktet til [-CH-0-]-gmppen. <D
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0310056 | 2003-05-01 | ||
PCT/GB2004/001831 WO2004096763A1 (en) | 2003-05-01 | 2004-04-29 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20055654D0 NO20055654D0 (no) | 2005-11-30 |
NO20055654L true NO20055654L (no) | 2006-01-31 |
Family
ID=33397041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20055654A NO20055654L (no) | 2003-05-01 | 2005-11-30 | Azetidinkarboksamidderivater og deres anvendelse ved behandling av CBI-reseptormediserte forstyrrelser |
Country Status (16)
Country | Link |
---|---|
US (1) | US7504522B2 (no) |
EP (1) | EP1620395B1 (no) |
JP (1) | JP2006525298A (no) |
KR (1) | KR20060010770A (no) |
CN (1) | CN1802350A (no) |
AT (1) | ATE453620T1 (no) |
AU (1) | AU2004234125A1 (no) |
BR (1) | BRPI0409938A (no) |
CA (1) | CA2524251A1 (no) |
DE (1) | DE602004024880D1 (no) |
EA (1) | EA010583B1 (no) |
MX (1) | MXPA05011670A (no) |
NO (1) | NO20055654L (no) |
NZ (1) | NZ543016A (no) |
WO (1) | WO2004096763A1 (no) |
ZA (1) | ZA200508831B (no) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276452A1 (en) * | 2003-05-01 | 2006-12-07 | Vernalis Research Limited | Use of azetidinecarboxamide derivatives in therapy |
US7485732B2 (en) | 2003-06-11 | 2009-02-03 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
CA2613678A1 (en) | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
US20080027087A1 (en) * | 2006-02-21 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | CB1 antagonists and inverse agonists |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
FR2925051B1 (fr) * | 2007-12-18 | 2010-05-21 | Sanofi Aventis | Derives d'azetidines,leur preparation et leur application en therapeutique |
PL2234966T3 (pl) * | 2007-12-18 | 2014-02-28 | Sanofi Sa | Pochodne azetydyn, ich wytwarzanie i zastosowanie ich w lecznictwie |
PT2009157006W (pt) * | 2008-06-26 | 2012-10-17 | Micro Labs Ltd | Processo de preparação de ebastina |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
ES2652662T3 (es) | 2011-02-25 | 2018-02-05 | Merck Sharp & Dohme Corp. | Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014210041A1 (en) | 2013-06-25 | 2014-12-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Service | Glucan-encapsulated sirna for treating type 2 diabetes mellitus |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN105218474B (zh) * | 2015-10-22 | 2017-12-05 | 山东国邦药业股份有限公司 | (4r,5r)‑2‑二氯甲基‑4,5‑二氢‑5‑(4‑甲砜基苯基)‑4‑恶唑甲醇的合成方法 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
JP7269943B2 (ja) | 2018-01-08 | 2023-05-09 | エフ. ホフマン-ラ ロシュ アーゲー | Magl阻害剤としてのオクタヒドロピリド[1,2-アルファ]ピラジン |
EP3669876A1 (en) * | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
CR20230115A (es) | 2020-09-03 | 2023-04-11 | Hoffmann La Roche | Compuestos heterocíclicos |
US11141404B1 (en) * | 2020-11-18 | 2021-10-12 | Anebulo Pharmaceuticals, Inc. | Formulations and methods for treating acute cannabinoid overdose |
CA3234167A1 (en) * | 2021-10-11 | 2023-04-20 | Joseph Fenton Lawler | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
WO2024073367A1 (en) * | 2022-09-26 | 2024-04-04 | Anebulo Pharmaceuticals, Inc. | Treatment of acute cannabinoid overdose |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261990A (en) * | 1979-03-09 | 1981-04-14 | Ciba-Geigy Corporation | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics |
JPH03264562A (ja) * | 1989-05-22 | 1991-11-25 | Hokuriku Seiyaku Co Ltd | ピペリジン誘導体 |
JP3194355B2 (ja) * | 1996-10-24 | 2001-07-30 | 宇部興産株式会社 | ピペリジン化合物及びその製法 |
JP4542263B2 (ja) * | 1998-01-23 | 2010-09-08 | バーナリス リサーチ リミテッド | Cns障害を処置するためのアゼチジンカルボキサミド誘導体 |
GB9917386D0 (en) * | 1999-07-23 | 1999-09-22 | Cerebrus Ltd | Chemical compounds-II |
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
US20060276452A1 (en) * | 2003-05-01 | 2006-12-07 | Vernalis Research Limited | Use of azetidinecarboxamide derivatives in therapy |
-
2004
- 2004-04-29 EA EA200501585A patent/EA010583B1/ru not_active IP Right Cessation
- 2004-04-29 AU AU2004234125A patent/AU2004234125A1/en not_active Abandoned
- 2004-04-29 AT AT04730296T patent/ATE453620T1/de not_active IP Right Cessation
- 2004-04-29 CA CA002524251A patent/CA2524251A1/en not_active Abandoned
- 2004-04-29 KR KR1020057020649A patent/KR20060010770A/ko not_active Application Discontinuation
- 2004-04-29 BR BRPI0409938-9A patent/BRPI0409938A/pt not_active IP Right Cessation
- 2004-04-29 US US10/552,575 patent/US7504522B2/en not_active Expired - Fee Related
- 2004-04-29 JP JP2006506198A patent/JP2006525298A/ja active Pending
- 2004-04-29 MX MXPA05011670A patent/MXPA05011670A/es active IP Right Grant
- 2004-04-29 CN CNA2004800115989A patent/CN1802350A/zh active Pending
- 2004-04-29 NZ NZ543016A patent/NZ543016A/en unknown
- 2004-04-29 EP EP04730296A patent/EP1620395B1/en not_active Expired - Lifetime
- 2004-04-29 DE DE602004024880T patent/DE602004024880D1/de not_active Expired - Fee Related
- 2004-04-29 WO PCT/GB2004/001831 patent/WO2004096763A1/en active Application Filing
-
2005
- 2005-10-31 ZA ZA200508831A patent/ZA200508831B/en unknown
- 2005-11-30 NO NO20055654A patent/NO20055654L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200501585A1 (ru) | 2006-06-30 |
EA010583B1 (ru) | 2008-10-30 |
CA2524251A1 (en) | 2004-11-11 |
BRPI0409938A (pt) | 2006-04-25 |
KR20060010770A (ko) | 2006-02-02 |
ZA200508831B (en) | 2007-03-28 |
US20070054891A1 (en) | 2007-03-08 |
NO20055654D0 (no) | 2005-11-30 |
CN1802350A (zh) | 2006-07-12 |
AU2004234125A1 (en) | 2004-11-11 |
DE602004024880D1 (de) | 2010-02-11 |
NZ543016A (en) | 2009-03-31 |
ATE453620T1 (de) | 2010-01-15 |
WO2004096763A1 (en) | 2004-11-11 |
US7504522B2 (en) | 2009-03-17 |
JP2006525298A (ja) | 2006-11-09 |
MXPA05011670A (es) | 2005-12-15 |
EP1620395B1 (en) | 2009-12-30 |
EP1620395A1 (en) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20055654L (no) | Azetidinkarboksamidderivater og deres anvendelse ved behandling av CBI-reseptormediserte forstyrrelser | |
NO20055655L (no) | Anvendelse av azetidinkarboksamidderivater i terapi | |
MX2007014400A (es) | Novedosos compuestos heterociclicos como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. | |
TW200833675A (en) | Nicotinamide derivatives | |
NZ561747A (en) | (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity | |
WO2008121861A3 (en) | Pyrazole and pyrrole compounds useful in treating iron disorders | |
NO20070249L (no) | Pyrrazolo-pyrimidin derivater | |
NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
MX2010002538A (es) | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas. | |
MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
TW200619212A (en) | Morpholine derivatives | |
TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
PL1745010T3 (pl) | Podstawione pochodne cykloheksylo-1,4-diaminy | |
EA200870074A1 (ru) | Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1 | |
RS20050892A (en) | Imidazole derivatives as glutamate receptor antagonists | |
TNSN07006A1 (en) | Novel heterocyclic compounds | |
SI1893589T1 (sl) | Substituirani N-benzo(d)izoksazol-3-il-aminski derivati kot inhibitorji mGluR5, serotonin-(5-HT) in noradrenalinskih receptorjev in njihova uporaba za pripravo zdravil | |
UA86873C2 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
TNSN06337A1 (en) | 6-substituted pyridoindolone derivatives production and therapeutic use thereof | |
SI1776339T1 (sl) | Derivati 3-(((4-fenil)-piperazin-1-il)-alkil)-3-alkil-1,3-dihidro-2H-indol-2-ona in sorodne spojine za zdravljenje motenj centralnega živčnega sistema | |
NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer | |
DK1756066T3 (da) | Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet | |
DE60224509D1 (de) | Imidazolderivate verwendbar als histamin h3 rezeptorliganden | |
EA200602080A1 (ru) | Пиперазиновые производные алкилоксиндолов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |